Adjunctive use of physostigmine salicylate (Anticholium®) in perioperative sepsis and septic shock: study protocol for a randomized, double-blind, placebo-controlled, monocentric trial (Anticholium® per Se)
Severe sepsis and septic shock remain a major challenge, even in modern intensive care. In Germany, about 68,000 patients die annually because of septic diseases, characterized by a complex systemic inflammatory response. Causal treatment of the underlying infection is essential for successful manag...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
10 November 2017
|
| In: |
Trials
Year: 2017, Jahrgang: 18 |
| ISSN: | 1468-6694 |
| DOI: | 10.1186/s13063-017-2231-x |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/s13063-017-2231-x Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s13063-017-2231-x 
|
| Verfasserangaben: | Johannes B. Zimmermann, Nadine Pinder, Thomas Bruckner, Monika Lehmann, Johann Motsch, Thorsten Brenner, Torsten Hoppe-Tichy, Stefanie Swoboda, Markus A. Weigand and Stefan Hofer |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 157169580X | ||
| 003 | DE-627 | ||
| 005 | 20230426124231.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180404s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13063-017-2231-x |2 doi | |
| 035 | |a (DE-627)157169580X | ||
| 035 | |a (DE-576)50169580X | ||
| 035 | |a (DE-599)BSZ50169580X | ||
| 035 | |a (OCoLC)1263971884 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Zimmermann, Johannes B. |d 1978- |e VerfasserIn |0 (DE-588)1052919960 |0 (DE-627)789310368 |0 (DE-576)408663421 |4 aut | |
| 245 | 1 | 0 | |a Adjunctive use of physostigmine salicylate (Anticholium®) in perioperative sepsis and septic shock |b study protocol for a randomized, double-blind, placebo-controlled, monocentric trial (Anticholium® per Se) |c Johannes B. Zimmermann, Nadine Pinder, Thomas Bruckner, Monika Lehmann, Johann Motsch, Thorsten Brenner, Torsten Hoppe-Tichy, Stefanie Swoboda, Markus A. Weigand and Stefan Hofer |
| 264 | 1 | |c 10 November 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 04.04.2018 | ||
| 520 | |a Severe sepsis and septic shock remain a major challenge, even in modern intensive care. In Germany, about 68,000 patients die annually because of septic diseases, characterized by a complex systemic inflammatory response. Causal treatment of the underlying infection is essential for successful management of sepsis, but the course can be positively influenced by supportive and adjuvant measures. The cholinergic anti-inflammatory pathway (CAP) represents a new approach to adjunctive therapy of septic diseases and can be pharmacologically activated by the acetylcholinesterase inhibitor physostigmine (Anticholium®). Promising effects can be found in several in vitro and in vivo models of sepsis, such as a reduction in pro-inflammatory cytokines and improved survival. | ||
| 650 | 4 | |a Antilirium | |
| 650 | 4 | |a Cholinergic anti-inflammatory pathway | |
| 650 | 4 | |a Cholinesterase inhibitor | |
| 650 | 4 | |a Continuous administration | |
| 650 | 4 | |a Critically ill | |
| 650 | 4 | |a Eserine | |
| 650 | 4 | |a Eseroline | |
| 650 | 4 | |a Intra-abdominal infection | |
| 650 | 4 | |a Physostigma venenosum | |
| 650 | 4 | |a Sequential Organ Failure Assessment (SOFA) score | |
| 700 | 1 | |a Pinder, Nadine |d 1985- |e VerfasserIn |0 (DE-588)112920605X |0 (DE-627)88385855X |0 (DE-576)486279235 |4 aut | |
| 700 | 1 | |a Bruckner, Thomas |d 1956- |e VerfasserIn |0 (DE-588)136046215 |0 (DE-627)574429298 |0 (DE-576)300798768 |4 aut | |
| 700 | 1 | |a Lehmann, Monika |e VerfasserIn |0 (DE-588)1141195305 |0 (DE-627)898948606 |0 (DE-576)494247568 |4 aut | |
| 700 | 1 | |a Motsch, Johann |d 1952- |e VerfasserIn |0 (DE-588)1059446626 |0 (DE-627)798468319 |0 (DE-576)415532876 |4 aut | |
| 700 | 1 | |a Brenner, Thorsten |d 1978- |e VerfasserIn |0 (DE-588)130125709 |0 (DE-627)491713363 |0 (DE-576)189360607 |4 aut | |
| 700 | 1 | |a Hoppe-Tichy, Torsten |e VerfasserIn |0 (DE-588)1095801376 |0 (DE-627)856418919 |0 (DE-576)467814597 |4 aut | |
| 700 | 1 | |a Swoboda, Stefanie |d 1974- |e VerfasserIn |0 (DE-588)128401591 |0 (DE-627)372642896 |0 (DE-576)297124838 |4 aut | |
| 700 | 1 | |a Weigand, Markus A. |d 1967- |e VerfasserIn |0 (DE-588)1064970435 |0 (DE-627)815375239 |0 (DE-576)424658666 |4 aut | |
| 700 | 1 | |a Hofer, Stefan |d 1971- |e VerfasserIn |0 (DE-588)122418506 |0 (DE-627)70590072X |0 (DE-576)187683867 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trials |d London : BioMed Central, 2000 |g 18(2017) Artikel-Nummer 530, 10 Seiten |h Online-Ressource |w (DE-627)326173552 |w (DE-600)2040523-6 |w (DE-576)107014556 |x 1468-6694 |7 nnas |a Adjunctive use of physostigmine salicylate (Anticholium®) in perioperative sepsis and septic shock study protocol for a randomized, double-blind, placebo-controlled, monocentric trial (Anticholium® per Se) |
| 773 | 1 | 8 | |g volume:18 |g year:2017 |a Adjunctive use of physostigmine salicylate (Anticholium®) in perioperative sepsis and septic shock study protocol for a randomized, double-blind, placebo-controlled, monocentric trial (Anticholium® per Se) |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13063-017-2231-x |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s13063-017-2231-x |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180404 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 122418506 |a Hofer, Stefan |m 122418506:Hofer, Stefan |d 910000 |d 910300 |e 910000PH122418506 |e 910300PH122418506 |k 0/910000/ |k 1/910000/910300/ |p 10 |y j | ||
| 998 | |g 1064970435 |a Weigand, Markus A. |m 1064970435:Weigand, Markus A. |d 910000 |d 910300 |e 910000PW1064970435 |e 910300PW1064970435 |k 0/910000/ |k 1/910000/910300/ |p 9 | ||
| 998 | |g 128401591 |a Swoboda, Stefanie |m 128401591:Swoboda, Stefanie |d 910000 |e 910000PS128401591 |k 0/910000/ |p 8 | ||
| 998 | |g 1095801376 |a Hoppe-Tichy, Torsten |m 1095801376:Hoppe-Tichy, Torsten |d 910000 |e 910000PH1095801376 |k 0/910000/ |p 7 | ||
| 998 | |g 130125709 |a Brenner, Thorsten |m 130125709:Brenner, Thorsten |d 910000 |d 910300 |d 50000 |e 910000PB130125709 |e 910300PB130125709 |e 50000PB130125709 |k 0/910000/ |k 1/910000/910300/ |k 0/50000/ |p 6 | ||
| 998 | |g 1059446626 |a Motsch, Johann |m 1059446626:Motsch, Johann |d 910000 |d 910300 |e 910000PM1059446626 |e 910300PM1059446626 |k 0/910000/ |k 1/910000/910300/ |p 5 | ||
| 998 | |g 1141195305 |a Lehmann, Monika |m 1141195305:Lehmann, Monika |d 910000 |d 913000 |e 910000PL1141195305 |e 913000PL1141195305 |k 0/910000/ |k 1/910000/913000/ |p 4 | ||
| 998 | |g 136046215 |a Bruckner, Thomas |m 136046215:Bruckner, Thomas |d 910000 |d 999701 |e 910000PB136046215 |e 999701PB136046215 |k 0/910000/ |k 1/910000/999701/ |p 3 | ||
| 998 | |g 112920605X |a Pinder, Nadine |m 112920605X:Pinder, Nadine |d 910000 |d 910300 |e 910000PP112920605X |e 910300PP112920605X |k 0/910000/ |k 1/910000/910300/ |p 2 | ||
| 998 | |g 1052919960 |a Zimmermann, Johannes B. |m 1052919960:Zimmermann, Johannes B. |d 910000 |d 910300 |e 910000PZ1052919960 |e 910300PZ1052919960 |k 0/910000/ |k 1/910000/910300/ |p 1 |x j | ||
| 999 | |a KXP-PPN157169580X |e 3004905566 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"157169580X","name":{"displayForm":["Johannes B. Zimmermann, Nadine Pinder, Thomas Bruckner, Monika Lehmann, Johann Motsch, Thorsten Brenner, Torsten Hoppe-Tichy, Stefanie Swoboda, Markus A. Weigand and Stefan Hofer"]},"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"10 November 2017"}],"relHost":[{"pubHistory":["1.2000 -"],"titleAlt":[{"title":"Current controlled trials in cardiovascular medicine"}],"part":{"text":"18(2017) Artikel-Nummer 530, 10 Seiten","volume":"18","year":"2017"},"id":{"eki":["326173552"],"issn":["1468-6694","1745-6215"],"zdb":["2040523-6"]},"origin":[{"dateIssuedDisp":"2000-","dateIssuedKey":"2000","publisherPlace":"London","publisher":"BioMed Central"}],"title":[{"title":"Trials","title_sort":"Trials"}],"note":["Gesehen am 26.09.22"],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"326173552","physDesc":[{"extent":"Online-Ressource"}],"disp":"Adjunctive use of physostigmine salicylate (Anticholium®) in perioperative sepsis and septic shock study protocol for a randomized, double-blind, placebo-controlled, monocentric trial (Anticholium® per Se)Trials"}],"person":[{"role":"aut","given":"Johannes B.","family":"Zimmermann","display":"Zimmermann, Johannes B."},{"family":"Pinder","given":"Nadine","role":"aut","display":"Pinder, Nadine"},{"family":"Bruckner","role":"aut","given":"Thomas","display":"Bruckner, Thomas"},{"display":"Lehmann, Monika","family":"Lehmann","role":"aut","given":"Monika"},{"display":"Motsch, Johann","family":"Motsch","given":"Johann","role":"aut"},{"display":"Brenner, Thorsten","family":"Brenner","given":"Thorsten","role":"aut"},{"display":"Hoppe-Tichy, Torsten","family":"Hoppe-Tichy","given":"Torsten","role":"aut"},{"display":"Swoboda, Stefanie","family":"Swoboda","given":"Stefanie","role":"aut"},{"family":"Weigand","given":"Markus A.","role":"aut","display":"Weigand, Markus A."},{"given":"Stefan","role":"aut","family":"Hofer","display":"Hofer, Stefan"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"note":["Gesehen am 04.04.2018"],"id":{"doi":["10.1186/s13063-017-2231-x"],"eki":["157169580X"]},"title":[{"subtitle":"study protocol for a randomized, double-blind, placebo-controlled, monocentric trial (Anticholium® per Se)","title_sort":"Adjunctive use of physostigmine salicylate (Anticholium®) in perioperative sepsis and septic shock","title":"Adjunctive use of physostigmine salicylate (Anticholium®) in perioperative sepsis and septic shock"}]} | ||
| SRT | |a ZIMMERMANNADJUNCTIVE1020 | ||